细菌系变异分析显示EPHB4R91H突变是多种原发性肺瘤的关键参与者
Jing Li1, Yanan Li2, Xinjuan Wang1
1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Jianshe East Road, Erqi District, Zhengzhou 450052, Henan, PR China.
Carcinogenesis
|November 22, 2024
概括
生殖线变化,特别是EPHB4R91H,与多重初级肺腺癌 (MPLA) 的发展有关. 这种突变通过激活EPHB4/ERK/JNK/MAPK通路来增强瘤细胞的增殖和入侵.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 多重原发性肺腺癌 (MPLA) 由于瘤异质性而存在治疗挑战.
- 假设生殖线的变化会影响MPLA的发展,独立于瘤异质性.
研究的目的:
- 为了确定与MPLA相关的候选生殖系改变.
- 调查MPLA病变发生过程中发现的生殖线变化的功能作用.
主要方法:
- 周围血液的全外体测序,以分析生殖线的变化.
- 对MPLA患者,单独肺腺癌患者和健康对照患者罕见的有害变化的比较分析.
- 针对性的桑格测序,以验证扩散MPLA患者的突变部位.
主要成果:
- 在MPLA患者和家属中发现了一种特定的罕见且有害的生殖系变异,EPHB4R91H.
- 发现EPHB4R91H在体外增强了A549细胞的增殖,迁移和入侵.
- EPHB4R91H突变增加了与以弗林B2的结合亲和力,激活了EPHB4/ERK/JNK/MAPK通路.
结论:
- 生殖线变化在多重初级肺腺癌的发展中起着重要作用.
- EPHB4R91H突变是MPLA发育的新型驱动因素,通过增强的林B2结合和下游通路激活促进瘤发生.
相关概念视频
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


